This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
=== Medical use === The appeal of conotoxins for creating pharmaceutical drugs is the precision and speed with which the chemicals act; many of the compounds target only a particular class of receptor. This means that they can reliably and quickly produce a particular effect on the body's systems without side effects; for example, almost instantly reducing heart rate or turning off the signaling of a single class of nerve, such as pain receptors. Ziconotide, a powerful atypical painkiller, was initially isolated from the venom of the magician cone snail, Conus magus. It was approved by the U.S. Food and Drug Administration in December 2004 under the name Prialt. Other drugs based on cone snail venom targeting Alzheimer's disease, Parkinson's disease, depression, and epilepsy are in clinical or preclinical trials. Many peptides produced by the cone snails show prospects for being potent pharmaceuticals, such as AVC1, isolated from the Australian species, the Queen Victoria cone, Conus victoriae, and have been highly effective in treating postsurgical and neuropathic pain, even accelerating recovery from nerve injury. Geography and tulip cone snails, as well as the Conus kinoshitai, are known to secrete a type of insulin that paralyzes nearby fish by causing hypoglycaemic shock. They are the only two non-human animal species known to use insulin as a weapon. Cone snail insulin is capable of binding to human insulin receptors and researchers are studying its use as a potent fast-acting therapeutic insulin.
rivalries between Nazi leaders for Hitler's favor that led to the "cumulative radicalization" of racial policy was Hitler always favored those with the most radical ideas. the tendency of the Nazis to define the volksgemeinschaft in a negative sense in terms of who was to be excluded together with a xenophobic and paranoid tendency to see Germany as besieged by external and internal enemies. Peukert wrote all "monocausal explanations of the 'Final Solution' are inadequate", but then asked if out of this "tangle of causes" one might find a "central thread" linking them all. Peukert suggested that this "thread" was not antisemitism-through he admitted that Jews were the largest single group of victims of the Nazi regime-but rather the "fatal racist dynamism present within the human and social sciences", which divided all people into terms of "value" and "non-value", and made the volkskörper (the collective "body" of the "German race") its main concern with the "selection" of those with healthy genes and the "eradication" of those with unhealthy genes. In this regard, Peukert noted the genocide against the Jews grew out of the Action T4 program which starting in January 1939 sought to liquidate all physically and mentally disabled Germans as a threat to the health of the volkskörper. Peukert wrote that it was not antisemitism per se that led to genocide, but rather the project to purge the volksgemeinschaft of those seen as carrying unhealthy genes that was the beginning of genocide, which started with the Action T4 program.
where z is the number of positive or negative charges of the ion, e is the elementary charge and m is the mass of the ion. An electric excitation signal having a frequency f will therefore resonate with ions having a mass-to-charge ratio m/z given by
==== Output ==== After an incident particle has fused with a parent nucleus, if the excitation energy is sufficient, the nucleus breaks into fragments. This is called scission, and occurs at about 10−20 seconds. The fragments can emit prompt neutrons at between 10−18 and 10−15 seconds. At about 10−11 seconds, the fragments can emit gamma rays. At 10−3 seconds β decay, β-delayed neutrons, and gamma rays are emitted from the decay products. Typical fission events release about two hundred million eV (200 MeV) of energy for each fission event. The exact isotope which is fissioned, and whether or not it is fissionable or fissile, has only a small impact on the amount of energy released. This can be easily seen by examining the curve of binding energy (image below), and noting that the average binding energy of the actinide nuclides beginning with uranium is around 7.6 MeV per nucleon. Looking further left on the curve of binding energy, where the fission products cluster, it is easily observed that the binding energy of the fission products tends to center around 8.5 MeV per nucleon. Thus, in any fission event of an isotope in the actinide mass range, roughly 0.9 MeV are released per nucleon of the starting element. The fission of 235U by a slow neutron yields nearly identical energy to the fission of 238U by a fast neutron. This energy release profile holds for thorium and the various minor actinides as well.
Sources: en.wikipedia.org
Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
Micrococcal nuclease (EC 3.1.31.1, S7 Nuclease, MNase, spleen endonuclease, thermonuclease, nuclease T, micrococcal endonuclease, nuclease T', staphylococcal nuclease, spleen phosphodiesterase, Staphylococcus aureus nuclease, Staphylococcus aureus nuclease B, ribonucleate (deoxynucleate) 3'-nucleotidohydrolase) is an endo-exonuclease that preferentially digests single-stranded nucleic acids. The rate of cleavage is 30 times greater at the 5' side of A or T than at G or C and results in the production of mononucleotides and oligonucleotides with terminal 3'-phosphates. The enzyme is also active against double-stranded DNA and RNA and all sequences will be ultimately cleaved. The enzyme has a molecular weight of 16.9kDa. The pH optimum is reported as 9.2. The enzyme activity is strictly dependent on Ca2+ and the pH optimum varies according to Ca2+ concentration. The enzyme is therefore easily inactivated by EGTA.
Bismuth is a chemical element; it has symbol Bi and atomic number 83. It is a post-transition metal and one of the pnictogens, with chemical properties resembling its lighter group 15 siblings arsenic and antimony. Elemental bismuth occurs naturally, and its sulfide and oxide forms are important commercial ores. The free element is 86% as dense as lead. It is a brittle metal with a silvery-white color when freshly produced. Surface oxidation generally gives samples of the metal a somewhat rosy cast. Further oxidation under heat can give bismuth a vividly iridescent appearance due to thin-film interference. Bismuth is the most diamagnetic element and of all the metals, it is among the most electrically resistive and least thermally conductive known. Bismuth was formerly understood to be the element with the highest atomic mass whose nuclei do not spontaneously decay, but in 2003, it was found to be very slightly radioactive. The metal's only primordial isotope, bismuth-209, undergoes alpha decay with a half-life roughly a billion times longer than the estimated age of the universe. Bismuth metal has been known since ancient times. Before modern analytical methods, bismuth's metallurgical similarities to lead and tin often led it to be confused with those metals. The etymology of "bismuth" is uncertain. The name may come from mid-16th-century neo-Latin translations of the German words weiße Masse or Wismuth, meaning "white mass", which were rendered as bisemutum or bisemutium. Bismuth compounds account for about half the global production of bismuth.
== History == A phase III trial for dasiglucagon was started in July 2017. In December 2017, Zealand (Copenhagen, Denmark) announced the initiation of a phase III trial for dasiglucagon, with the intention of submitting positive outcomes to the US Food and Drug Administration (FDA) in 2019. The FDA approved dasiglucagon based on evidence from two clinical trials conducted in adults with type 1 diabetes (169 participants) and one clinical trial conducted in pediatric participants older than six years with type 1 diabetes (31 participants). The trials were conducted in the following five countries: United States, Germany, Austria, Canada, and Slovenia. The same trials were used to assess the safety and efficacy of dasiglucagon: adult Trials A and B and pediatric Trial C. In all trials, participants were randomized into one of three groups: one group received dasiglucagon, one group received placebo, and one group received glucagon for injection (a similar drug that is FDA approved for the same purpose as dasiglucagon). In all groups, participants were given insulin to decrease their blood sugar to a low level (hypoglycemia). Subjects received a single injection of either dasiglucagon, placebo, or glucagon for injection, and the ability of the treatment to increase the participants' blood sugar was evaluated.
Trump's 2024 presidential campaign refused to release basic medical records on Trump's health for a significant period, with the most recent release being in 2015. A number of official reports have since been made, concluding that Trump was in "excellent health" and "fully fit" to serve as president. Beginning in 2025, concerns grew over Trump's stamina after he appeared to fall asleep during multiple meetings. By May 2026, multiple polls showed a majority of Americans did not believe Trump was mentally fit to be president. Overall concerns have continued to abound throughout his second presidency, with both Trump insiders and outside critics directly discussing supposed health risks and their future impacts, up to and including a presidential succession by Vice President JD Vance.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.